Two patients who have participated in clinical trials with psychedelics have founded a non-profit aimed at representing the voice of the participants of psychedelic studies and advocating for the unique safety requirements of psychedelic therapy.
As Vardit Kohn first reported in Open Foundation, Ian Roullier and Leonie Schneider recently launched PsyPA.
“The focus should be on the psychotherapy, not the psychedelic aspect of the process,” they said.
Through connecting and empowering patients via consultancy and advocacy services, PsyPAN aims to give a collective voice for all participants and to help improve participant safety and wellbeing by building best practices across all levels of the global psychedelics sector.
Founders Roullier and Schneider were themselves participants in clinical trials using psilocybin and DMT to treat depression. Roullier, who suffered from depression and anxiety for most of his adult life, enrolled in two psilocybin pilot studies in 2015 and 2019, and that has proven to be the most effective treatment for his mental health to date.
His story has …